Clinical Trial Update: Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period [Phase 3]

View source ↗

Summary

Phase 3 trial comparing an insulin glargine/lixisenatide fixed-ratio combination to a GLP-1 receptor agonist in type 2 diabetes, with an extension period; resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• insulin glargine/lixisenatide fixed-ratio combination (insulin glargine, lixisenatide)

Snippet

Sponsor: Sanofi | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2019-06-12